Life science investment firm Emergent Medical Partners LP has raised nearly $70 million in a pooled investment fund over the past four-and-a-half years, according to two U.S. Securities and Exchange Commission filings on Thursday (here and here).
The Portolo Valley, California firm led by medical device pioneer Dr. Thomas Fogarty (one of MedCity News readers’ choices for the would-be Mount Rushmore of med tech) takes on device companies in all areas of medicine, with a particular interest in cardiovascular and orthopedic surgery.
Emergent’s portfolio contains Ardian, a medical device company acquired by Medtronic in 2011; Evalve, a cardiac device company acquired by Abbott in 2009; and diagnostic company HeartFlow, among others.
A call to the firm for further detail was not returned.
By Deanna Pogorelc MedCity News
Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.More posts by Author
- Get Livefyre
- FAQ
